Shuichan Xu

机构：Bristol-Myers Squibb (United States) · ORCID：0009-0001-9105-4199

发表论文 86 篇 · 总被引 4898 次 · h-index 28

代表论文

Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation (2023 · Journal of Medicinal Chemistry · 被引 53)
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells (2024 · Nature Communications · 被引 45)
Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer (2025 · Clinical Cancer Research · 被引 14)
Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer (2024 · Cancer Research · 被引 4)
Abstract 6378: Brain-penetrant molecular glue degraders targeting ALK via a novel degron: a potential therapeutic approach for ALK-positive NSCLC (2025 · Cancer Research · 被引 2)
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365 (2026 · Figshare)